72 Pinchas Rosen Street
|
Tel-Aviv 6951294, Israel
|
(Address of Principal Executive Offices)
|
Exhibit
|
||
Number
|
Description of Exhibit
|
|
99.1
|
Press Release, dated October 29, 2014.
|
|
99.2
|
Non-Binding Translation of the consolidated version of the Company’s Memorandum of Association incorporating all previous amendments.
|
COMPUGEN LTD.
|
|||
Date: October 29, 2014
|
By:
|
/s/
Ari Krashin
|
|
Ari Krashin
CFO
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
2014
Unaudited
|
2013
Unaudited
|
2014
Unaudited
|
2013
Unaudited
|
|||||||||||||
Revenues
|
1,718
|
1,590
|
5,815
|
1,774
|
||||||||||||
Cost of revenues
|
741
|
1,465
|
2,357
|
1,699
|
||||||||||||
Gross profit
|
977
|
125
|
3,458
|
75
|
||||||||||||
Operating expenses
|
||||||||||||||||
Research and development expenses, net
|
3,910
|
2,842
|
10,226
|
9,018
|
||||||||||||
Marketing and business development expenses
|
156
|
415
|
438
|
767
|
||||||||||||
General and administrative expenses
|
1,504
|
1,270
|
4,016
|
3,375
|
||||||||||||
Total operating expenses *
|
5,570
|
4,527
|
14,680
|
13,160
|
||||||||||||
Operating loss
|
(4,593
|
)
|
(4,402
|
)
|
(11,222
|
)
|
(13,085
|
)
|
||||||||
Financing income (loss), net **
|
(802
|
)
|
(185
|
)
|
1,670
|
2,085
|
||||||||||
Net loss before taxes
|
(5,395
|
)
|
(4,587
|
)
|
(9,552
|
)
|
(11,000
|
)
|
||||||||
Taxes on income
|
-
|
155
|
60
|
155
|
||||||||||||
Net loss
|
(5,395
|
)
|
(4,742
|
)
|
(9,612
|
)
|
(11,155
|
)
|
||||||||
Basic and diluted net loss per ordinary share
|
(0.11
|
)
|
(0.12
|
)
|
(0.20
|
)
|
(0.29
|
)
|
||||||||
Weighted average number of Ordinary shares used in computing basic and diluted net loss per share
|
49,089,165
|
39,145,119
|
47,021,655
|
38,217,843
|
* Includes non-cash stock based compensation.
|
** Includes non-cash income (expenses) related to the Baize research and development funding arrangement.
|
September 30,
2014
|
December 31,
2013
|
|||||||
Unaudited
|
Audited
|
|||||||
ASSETS
|
||||||||
Current assets
|
||||||||
Cash, cash equivalents and short-term bank deposits
|
$
|
107,383
|
$
|
46,766
|
||||
Investment in Evogene
|
1,453
|
4,565
|
||||||
Other accounts receivable and prepaid expenses
|
1,272
|
1,885
|
||||||
Total current assets
|
110,108
|
53,216
|
||||||
Non-current investments
|
||||||||
Severance pay fund
|
2,075
|
2,129
|
||||||
Total non-current investments
|
2,075
|
2,129
|
||||||
Non-current prepaid expenses
|
100
|
158
|
||||||
Property and equipment, net
|
2,349
|
1,208
|
||||||
Total assets
|
$
|
114,632
|
$
|
56,711
|
||||
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
||||||||
Current liabilities
|
||||||||
Other accounts payable, accrued expenses and trade payables
|
$
|
3,091
|
$
|
2,421
|
||||
Deferred revenues
|
2,018
|
5,318
|
||||||
Total current liabilities
|
5,109
|
7,739
|
||||||
Non-current liabilities
|
||||||||
Research and development funding arrangement
|
526
|
13,189
|
||||||
Deferred revenues
|
326
|
1,454
|
||||||
Accrued severance pay
|
2,356
|
2,441
|
||||||
Total non-current liabilities
|
3,208
|
17,084
|
||||||
Total shareholders’ equity
|
106,315
|
31,888
|
||||||
Total liabilities and shareholders’ equity
|
$
|
114,632
|
$
|
56,711
|
|
1.
|
The name of the Company
:
|
קומפיוג'ן בע"מ
COMPUGEN LTD.
|
|
2.
|
The purpose of the Company is to engage in any lawful act or activity for which companies may be organized under the Israeli Companies Law, 1999.
|
|
3.
|
Members Liability
:
|
|
4.
|
Authorized Share Capital
:
|
|
5.
|
Changes to the Memorandum
|
|
6.
|
We the undersigned are desirous of being formed into a Company in pursuant to this Memorandum of Association and we respectively agree to take the number of shares in the capital of the Company set opposite our respective names.
|